此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

怀疑是恶性胸腔积液的患者的胸膜镜检查首先与胸腔​​穿刺术 (PERFECT-MPE)

2026年10月1日 更新者:Udit Chaddha、Icahn School of Medicine at Mount Sinai

This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.

研究概览

详细说明

This is a randomized control trial of patients with suspected malignant pleural effusions comparing patients who undergo either pleuroscopy or thoracentesis as the first diagnostic test. Both procedures are considered standard of care for this diagnosis but it is unknown which one provides more adequate biopsy samples and achieves faster diagnosis and shorter time to oncologic treatment. Currently, most patients undergo thoracentesis first and, if this is inadequate for diagnosis, they then undergo pleuroscopy for further biopsy samples. This study seeks to assess whether patients who undergo pleuroscopy as the first test obtain adequate biopsy samples and a faster path to further oncologic care compared to patients who undergo thoracentesis first. Patients will be recruited and randomized in a 1:1 manner.

Ultrasound is routinely used prior to the procedure and a chest x-ray is done after the procedure. Any other imaging will be determined by clinic need only. No imaging will be done for research purposes. No additional samples will be collected other than what is necessary for diagnostic purposes. In patients who have a non-diagnostic thoracentesis, the participants will be referred for pleuroscopy as the next diagnostic step. In the rare case that pleuroscopy does not achieve adequate diagnosis, the next step would be a liquid biopsy (non-invasive serologic testing for oncologic markers.) The need for liquid biopsy in participants in this study will be determined on a case-by-case basis depending on the clinical concern for malignancy.

研究类型

介入性

注册 (实际的)

75

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • New York、New York、美国、10019
        • Mount Sinai West
      • New York、New York、美国、10029
        • Mount Sinai Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Referral for diagnostic pleural procedure.
  • Age ≥ 18 years.
  • Suspected malignant pleural effusion (Suggestive radiologic appearance (based on computed tomography or positron emission tomography) OR suspected cancer with associated effusion.)

Exclusion Criteria:

  • Inability to provide informed consent.
  • Needs emergent drainage.
  • Pleural effusion is known to be malignant.
  • Suspected transudative, infectious or inflammatory effusion etiology.
  • Having prior inconclusive/non-diagnostic thoracentesis or pleuroscopy.
  • Patient is deemed by the clinical team to be more appropriate for VATS biopsy.
  • Terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities.
  • Pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Pleuroscopy first

Participants will undergo pleuroscopy first

Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis.

有源比较器:Thoracentesis first

Participants will undergo thoracentesis first

Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of biopsies adequate for definitive diagnosis
大体时间:6 months

Proportion of biopsies adequate for definitive diagnosis

6 months

次要结果测量

结果测量
措施说明
大体时间
Time from initial visit with pulmonologist to procedure
大体时间:6 months

Time from initial visit with pulmonologist to procedure

6 months
Time from initial procedure to diagnosis
大体时间:6 months

Time from initial procedure to diagnosis

6 months
Time from initial visit with pulmonologist to diagnosis
大体时间:6 months

Time from initial visit with pulmonologist to diagnosis

6 months
Time from initial visit with pulmonologist to seeing oncologist
大体时间:6 months

Time from initial visit with pulmonologist to seeing oncologist

6 months
Time from initial visit with pulmonologist to starting treatment
大体时间:6 months

Time from initial visit with pulmonologist to starting treatment

6 months
Time from seeing oncologist to starting treatment
大体时间:6 months

Time from seeing oncologist to starting treatment

6 months
Frequency of procedure-related complications
大体时间:6 months

Frequency of procedure-related complications

6 months
Frequency of additional diagnostic testing
大体时间:6 months

Frequency of additional diagnostic testing

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Udit Chaddha, MBBS、MOUNT SINAI HOSPITAL

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月19日

初级完成 (实际的)

2026年8月30日

研究完成 (实际的)

2026年8月30日

研究注册日期

首次提交

2025年3月19日

首先提交符合 QC 标准的

2025年3月19日

首次发布 (实际的)

2025年3月25日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • STUDY-24-00999

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All of the individual participant data collected during the trial, after deidentification.

IPD 共享时间框架

Immediately following publication. No end date.

IPD 共享访问标准

Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose.

Any purpose. Proposals should be directed to udit.chaddha@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link tbd).

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅